Below are the most recent publications written about "Antibody-Dependent Cell Cytotoxicity" by people in Profiles.
-
Maskalenko NA, Zahroun S, Tsygankova O, Anikeeva N, Sykulev Y, Campbell KS. The Fc?RIIIA (CD16) L48-H/R Polymorphism Enhances NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity by Promoting Serial Killing. Cancer Immunol Res. 2025 03 04; 13(3):417-429.
-
Kinder M, Bahlis NJ, Malavasi F, De Goeij B, Babich A, Sendecki J, Rusbuldt J, Bellew K, Kane C, Van de Donk NWCJ. Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma. Haematologica. 2021 07 01; 106(7):2004-2008.
-
Li C, Chong G, Zong G, Knorr DA, Bournazos S, Aytenfisu AH, Henry GK, Ravetch JV, MacKerell AD, Wang LX. Site-Selective Chemoenzymatic Modification on the Core Fucose of an Antibody Enhances Its Fc? Receptor Affinity and ADCC Activity. J Am Chem Soc. 2021 05 26; 143(20):7828-7838.
-
Frerichs KA, Broekmans MEC, Marin Soto JA, van Kessel B, Heymans MW, Holthof LC, Verkleij CPM, Boominathan R, Vaidya B, Sendecki J, Axel A, Gaudet F, Pillarisetti K, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ. Preclinical Activity of JNJ-7957, a Novel BCMA?CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. Clin Cancer Res. 2020 05 01; 26(9):2203-2215.
-
Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney AY, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. Cancer Immunol Res. 2019 10; 7(10):1633-1646.
-
Giddens JP, Lomino JV, DiLillo DJ, Ravetch JV, Wang LX. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody. Proc Natl Acad Sci U S A. 2018 11 20; 115(47):12023-12027.
-
Tomalka AG, Resto-Garay I, Campbell KS, Popkin DL. In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol. 2018; 9:2552.
-
Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, Sato N, DiLillo DJ, Bamford RN, Ravetch JV, Waldmann TA. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci U S A. 2018 11 13; 115(46):E10915-E10924.
-
Abreu-Mota T, Hagen KR, Cooper K, Jahrling PB, Tan G, Wirblich C, Johnson RF, Schnell MJ. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. Nat Commun. 2018 10 11; 9(1):4223.
-
Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX. Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci U S A. 2017 03 28; 114(13):3485-3490.